KBY Biotech Indexv0.0.34
Search
← Pipeline|Ceviglumide

Ceviglumide

Phase 1
416-6129
By PharmaEngine
Source: Trial-derived·Trials: 2
Modality
Gene Therapy
MOA
MDM2i
Target
PLK4
Pathway
Wnt
Gastric CaCervical CaObesity
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
Dec 2018
→ Dec 2029
Phase 1Current
NCT03563348
237 pts·Gastric Ca
2021-12→2029-12·Terminated
NCT07415924
2,035 pts·Obesity
2018-12→2026-12·Terminated
2,272 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-219mo awayInterim· Obesity
2029-12-123.7y awayInterim· Gastric Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Termina…
P1
Termina…
Catalysts
Interim
2026-12-21 · 9mo away
Obesity
Interim
2029-12-12 · 3.7y away
Gastric Ca
Terminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT03563348Phase 1Gastric CaTerminated237NT-proBNP
NCT07415924Phase 1ObesityTerminated2035VA
Competitors (10)
DrugCompanyPhaseTargetMOA
DoxacapivasertibEli LillyPhase 3APOC3MDM2i
BMY-8678Bristol-Myers SquibbApprovedRETMDM2i
AMG-415AmgenPhase 1CDK2MDM2i
GIL-2037Gilead SciencesApprovedKRASG12DMDM2i
BemanesiranBioNTechPhase 3PLK4HPK1i
CapiglumideBioNTechPreclinicalCGRPMDM2i
PeminaritideSareptaNDA/BLAPLK4JAK1/2i
PexaosocimabUnited TherapeuticsNDA/BLAPLK4KRASG12Ci
RimasertibExelixisPhase 3B7-H3MDM2i
PolalucimabJazz PharmaPreclinicalPLK4EZH2i